Geron (GERN) Expected to Announce Quarterly Earnings on Wednesday

Geron (NASDAQ:GERN) is expected to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

Geron Trading Down 5.9%

Shares of GERN stock opened at $1.77 on Tuesday. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -14.75 and a beta of 0.62. The company has a current ratio of 5.96, a quick ratio of 4.87 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average price of $1.45 and a 200 day moving average price of $1.34. Geron has a twelve month low of $1.04 and a twelve month high of $2.58.

Analyst Ratings Changes

Several brokerages recently issued reports on GERN. TD Cowen reissued a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (e+)” rating on shares of Geron in a report on Wednesday, January 28th. Needham & Company LLC dropped their target price on Geron from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. UBS Group reissued a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. Four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $2.75.

Hedge Funds Weigh In On Geron

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brevan Howard Capital Management LP lifted its stake in shares of Geron by 656.7% during the third quarter. Brevan Howard Capital Management LP now owns 269,528 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 233,911 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Geron by 56.1% during the 4th quarter. XTX Topco Ltd now owns 258,397 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 92,881 shares during the period. Raymond James Financial Inc. lifted its position in Geron by 50.5% during the 2nd quarter. Raymond James Financial Inc. now owns 214,771 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 72,055 shares in the last quarter. Virtu Financial LLC purchased a new position in Geron in the 4th quarter worth approximately $171,000. Finally, Mercer Global Advisors Inc. ADV grew its position in Geron by 104.4% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 91,619 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 46,801 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.